These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 19709997

  • 1. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J.
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [Abstract] [Full Text] [Related]

  • 2. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER, Semelka RC.
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [Abstract] [Full Text] [Related]

  • 3. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [Abstract] [Full Text] [Related]

  • 4. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
    Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL.
    Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
    [Abstract] [Full Text] [Related]

  • 5. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
    Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A.
    Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
    [Abstract] [Full Text] [Related]

  • 6. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M, Boateng F, Patel SS, Masood SF, Mahajan P, Patel N, Murray B.
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ, Im K, Broome DR.
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [Abstract] [Full Text] [Related]

  • 8. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine.
    Hope TA, Herfkens RJ, Denianke KS, LeBoit PE, Hung YY, Weil E.
    Invest Radiol; 2009 Mar; 44(3):135-9. PubMed ID: 19151610
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incidence of immediate gadolinium contrast media reactions.
    Prince MR, Zhang H, Zou Z, Staron RB, Brill PW.
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [Abstract] [Full Text] [Related]

  • 12. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A.
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
    Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J.
    J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
    [Abstract] [Full Text] [Related]

  • 15. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis.
    Steger-Hartmann T, Hofmeister R, Ernst R, Pietsch H, Sieber MA, Walter J.
    Invest Radiol; 2010 Sep; 45(9):520-8. PubMed ID: 20644486
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of older generations of gadolinium in mild-to-moderate renal failure.
    Khatami SM, Mahmoodian M, Zare E, Pashang M.
    Ren Fail; 2012 Sep; 34(2):176-80. PubMed ID: 22260266
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.